

Amendments to the Claims:

The following represents a complete listing of the claims in this application indicating the present status of each, including any amendments sought to be entered at this time. Any claims that have been canceled or withdrawn have been canceled or withdrawn without prejudice or disclaimer of any subject matter therein. The applicant specifically reserves the right to pursue any and all such claims in continuing and/or divisional applications. In this paper, claim 43 has been amended. Claims 43-67 are pending in this application. Claims 49 and 57-67 presently stand as being withdrawn. Thus, claims 43-48 and 50-56 remain under consideration.

Listing of Claims

1-42 (Canceled).

43 (currently amended). A method of making a viral particle having a modified cell binding activity comprising:

- (i) providing a viral packaging cell containing viral nucleic acid encoding an enveloped viral particle, wherein said viral particle is enveloped using an envelope unable to naturally bind to cells of a species being targeted, said viral particle having in a first cell binding activity wherein the viral packaging cell also contains nucleic acid encoding a passenger peptide binding moiety designed to modify said first cell binding activity of said viral particle;

(ii) expressing the viral nucleic acid and nucleic acid encoding the passenger peptide binding moiety and incorporating said passenger peptide binding moiety into said packaging cell membrane so that a viral particle buds from a said packaging cell membrane and the passenger peptide binding moiety is provided at a cell membrane ~~such that~~ thereby allowing the passenger peptide binding moiety ~~is~~ to be incorporated into the viral particle to modify its first cell binding activity, and wherein the passenger peptide binding moiety is other than a chimeric or fusion protein and wherein said passenger peptide is other than one derived from the virus or said packaging cell.

44 (previously presented). A method as in claim 43 wherein the peptide binding moiety is provided at an outer plasma membrane of the cell.

45 (previously presented). A method as in claim 43 wherein the viral particle is derived from a retroviral vector.

46 (previously presented). A method as in claim 43 wherein the passenger peptide binding moiety is selected from the group consisting of cell growth factors, antibodies or antigen-binding fragments thereof, moieties that recognize a target cell-specific surface antigen, and moieties that are at least a part of a member of a binding pair comprising a target -- cell specific cell -- surface receptor and its ligand.

47(previously present). A method as in claim 43 wherein the passenger peptide binding moiety is membrane-bound stem cell factor.

48(previously presented). A method as in claim 43 wherein the viral packaging cell line comprises additional nucleic acid which can be expressed to provide a bioactive agent which is active in or on a target cell.

49(withdrawn). A method as in claim 48 including employing the bioactive agent for a use selected from the group consisting of the prevention and/or treatment and/or diagnosis of a disease or disorder.

50(previously presented). A method as in claim 48 wherein the bioactive agent has a direct or indirect cytotoxic function.

51(previously presented). A method as in claim 50 wherein the bioactive agent is any one selected from the group consisting of ricin; tumour necrosis factor; interleukin-2; interferon-gamma; ribonuclease; deoxyribonuclease; Pseudomonas exotoxin A; and caspase.

52(previously presented). A method as in claim 48 wherein the bioactive agent is an enzyme capable of converting a relatively non-toxic pro-drug into a cytotoxic drug.

53(previously presented). A method as in claim 52 wherein the bioactive agent is either cytosine deaminase or thymidine kinase.

54(previously presented). A method as in claim 43 wherein the modified cell binding activity allows the viral particle to bind to a target cell.

55(previously presented). A method as in claim 54 wherein the target cell is selected from the group consisting of mammalian cells, human cells, quiescent cells, human haematopoietic stem cells, cancer cells and mammalian T-cells.

56(previously presented). A viral particle having a modified cell binding activity obtainable by a method as in claim 43 wherein the modified cell binding activity is conferred by a peptide other than a chimaeric viral envelope polypeptide.

57(withdrawn). A method or preparing an enriched population of a target cell type from a larger population of cells comprising:

- (i) exposing viral particles as in claim 56, having a modified binding activity for target cells, to a population of cells comprising the target cell type to permit binding to the viral particles;
- (ii) separating viral particles bound to target cells from the population of cells;
- (iii) optionally, subsequently removing the viral particles from the target cells.

58(withdrawn). A method as in claim 43 including enriching the titre of viral particles incorporating a passenger peptide binding moiety from a population of viral particles obtainable by

- (i) providing a support to which the passenger peptide binding moiety binds; and
- (ii) exposing the population of viral particles to the support; and
- (iii) optionally, isolating the viral particles which bind to the support from the viral particles which do not bind to the support.

59(withdrawn). A preparation of viral particles obtainable by the method as in claim 58 enriched for viral particles incorporating a passenger peptide binding moiety, the preparation having a titre of the viral particles of at least 10^5 ifu/ml.

60(withdrawn). A preparation as in claim 59 further comprising a pharmaceutically acceptable excipient and/or carrier.

61(withdrawn). A preparation as in claim 59 wherein said preparation is used as an ingredient in a medicament for the diagnosis and/or prevention and/or treatment of a disease or a disorder selected from the group consisting of arthritis and cancer, including ovarian cancer.

62(withdrawn). A preparation as in claim 61 wherein the virus particle incorporates a binding molecule which binds to CD5 as a passenger peptide binding moiety.

63(withdrawn). A preparation as in claim 61 wherein the viral particle incorporates membrane - bound stem cell factor as a passenger peptide binding moiety.

64(withdrawn). A preparation as in claim 61 wherein the viral particle incorporates membrane - bound stem cell factor as a passenger peptide binding moiety and wherein the disease or disorder is selected from the group consisting of cancers including ovarian cancer.

65(withdrawn). A preparation as in claim 61 wherein the viral particle includes a gene encoding an OPCML polypeptide.

66(withdrawn). A preparation as in claim 61 suitable for insertion into the genome of a population of cells in vivo by implantation into bone marrow or by infusion into a blood.

67(withdrawn). A preparation of viral particles as in claim 61 wherein the preparation is selected from the group consisting of vaccines and preparations suitable for presenting antigenic peptides to mammalian T-cells.